# NPK International

Type: Company (NPK)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/npk-international
Canonical HTML page: https://getbiobrief.com/entity/npk-international

## Recent coverage (1 stories)

### Incyte Q2 Portfolio Surge: $1.49B Revenue, Jakafi XR Launch Underway
2026-08-01 00:24:08 · Sentiment: Positive · Impact: 6/10 · Sources: 4

Incyte's Q2 net product sales hit $1.49 billion on a 40% jump, powered by Jakafi's 7% growth and a one-time OPZELURA CMS benefit. The biotech raised full-year 2026 revenue guidance to $5.13-5.26 billion and is advancing Jakafi XR with formulary wins, targeting 3-5% demand share by year-end.
Full story: https://getbiobrief.com/story/incyte-q2-2026-biotech-pharma-earnings

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.